Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Valneva SE
  6. Summary
    VLA   FR0004056851

VALNEVA SE

(VLA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
04/19/2021 04/20/2021 04/21/2021 04/22/2021 04/23/2021 Date
13.12(c) 12.78(c) 11.99(c) 11.94(c) 11.46 Last
1 267 304 1 002 045 3 129 053 1 258 862 1 055 806 Volume
+4.13% -2.59% -6.18% -0.42% -4.02% Change
More quotes
Financials
Sales 2021 185 M 223 M 223 M
Net income 2021 68,1 M 82,2 M 82,2 M
Net cash position 2021 30,5 M 36,8 M 36,8 M
P/E ratio 2021 17,9x
Yield 2021 -
Sales 2022 598 M 722 M 722 M
Net income 2022 289 M 349 M 349 M
Net cash position 2022 36,2 M 43,7 M 43,7 M
P/E ratio 2022 3,77x
Yield 2022 -
Capitalization 1 096 M 1 316 M 1 321 M
EV / Sales 2021 5,77x
EV / Sales 2022 1,77x
Nbr of Employees 500
Free-Float 69,8%
More Financials
Company
Valneva SE is a specialty vaccine company providing prevention against diseases with major unmet medical needs. Valneva SE's portfolio includes two vaccines for travelers: IXIARO®/JESPECT® indicated for the prevention of Japanese encephalitis and DUKORAL® indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC. The group also has a portfolio of vaccines in development... 
More about the company
Notations Surperformance© of Valneva SE
Trading Rating : Investor Rating :
More Ratings
All news about VALNEVA SE
04/22GLOBAL MARKETS LIVE : Chevron, Toyota, Sony...
04/22DYNAVAX TECHNOLOGIES  : Says France's Valneva Starts Late-Stage Study of COVID-1..
MT
04/22VALNEVA  : Starts Late-Stage Study Of COVID-19 Vaccine Shot
MT
04/21Valneva Initiates Phase 3 Clinical Trial for its Inactivated, Adjuvanted COVI..
GL
04/21GLOBAL MARKETS LIVE : Ericsson, Netflix, Roche...
04/21VALNEVA  : To Deprioritize Vaccine Supply Negotiations With EU Amid Zero Progres..
MT
04/20Valneva Switches Focus to Bilateral Discussions to Supply its Inactivated, Ad..
GL
04/12Valneva Completes Recruitment for Pivotal Phase 3 Trial of Chikungunya Vaccin..
GL
04/12VALNEVA  : Announces Publication of 2020 Universal Registration Document and Pro..
AQ
04/12Vaccine Maker Valneva Seeks Dual-Listing in US
MT
04/10VALNEVA  : Files Registration Statement for Proposed United States Initial Publi..
AQ
04/10VALNEVA  : Announces Publication of 2020 Universal Registration Document and Pro..
AQ
04/09VALNEVA SE  : Report
CO
04/08ORIGINAL-RESEARCH  : Valneva SE (von First Berlin Equity Research GmbH): Kaufen
DJ
04/06SECTOR UPDATE : Health Care Stocks Advance Pre-Bell Tuesday
MT
More news
News in other languages on VALNEVA SE
11:53aVALNEVA  : plus forte baisse de l'indice SBF 120 à la clôture du vendredi 23 avr..
04/22CORONA-BLOG/Indische Corona-Mutante erstmals in Belgien entdeckt
04/22CORONA-BLOG/GROSSBRITANNIEN  : 168 Blutgerinnsel-Fälle in Zusammenhang mit Astraz..
04/22CORONA-BLOG/Erste Corona-Fälle am Mount Everest gemeldet
04/22CORONA-BLOG/EU verzichtet auf Bestellung zusätzlicher Astrazeneca-Dosen
More news
Stock Trading Strategies
VALNEVA SE - 04/08
Volatility should make a big comeback
BUY
More Stock Trading Analysis
Chart VALNEVA SE
Duration : Period :
Valneva SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VALNEVA SE
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 12,54 €
Last Close Price 11,94 €
Spread / Highest target 13,1%
Spread / Average Target 5,03%
Spread / Lowest Target -10,4%
EPS Revisions
Managers and Directors
NameTitle
Thomas Lingelbach Co-President & Chief Executive Officer
Franck Charles Marie Grimaud Co-President & Chief Business Officer
Frédéric Grimaud Chairman-Supervisory Board
Michael Möhlen Vice President-Technical Development
Andreas Meinke VP-Preclinical & Translational Research
Sector and Competitors
1st jan.Capitalization (M$)
VALNEVA SE54.06%1 316
MODERNA, INC.60.91%67 328
LONZA GROUP AG-0.91%45 595
IQVIA HOLDINGS INC.26.10%43 328
CELLTRION, INC.-19.78%35 120
SEAGEN INC.-17.98%26 045